<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tumor necrosis factor-alpha inhibitors: An overview of adverse effects</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tumor necrosis factor-alpha inhibitors: An overview of adverse effects</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tumor necrosis factor-alpha inhibitors: An overview of adverse effects</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce Kirkham, BA, MD, FRCP, FRACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel E Furst, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 23, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Inhibitors of tumor necrosis factor (TNF)-alpha are important treatments in a number of inflammatory conditions, including rheumatoid arthritis (RA), spondyloarthritis, psoriasis, and inflammatory bowel disease (IBD). TNF-alpha inhibitors offer a targeted strategy that contrasts with the nonspecific immunosuppressive agents traditionally used to treat most inflammatory diseases. However, multiple adverse effects of TNF-alpha inhibition have been identified through both clinical trials and post-marketing surveillance. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Injection site reactions</p><p class="bulletIndent1"><span class="glyph">●</span>Infusion reactions</p><p class="bulletIndent1"><span class="glyph">●</span>Neutropenia</p><p class="bulletIndent1"><span class="glyph">●</span>Infections</p><p class="bulletIndent1"><span class="glyph">●</span>Demyelinating disease</p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure (HF)</p><p class="bulletIndent1"><span class="glyph">●</span>Cutaneous reactions</p><p class="bulletIndent1"><span class="glyph">●</span>Malignancy</p><p class="bulletIndent1"><span class="glyph">●</span>Induction of autoimmunity</p><p></p><p>Problems associated with injection site reactions, infusion reactions, neutropenia, demyelinating disease, heart failure, and some less common adverse effects will be reviewed here. Other major complications of TNF-alpha therapy, such as tuberculosis, other infections, malignancy, and induction of autoimmunity, are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1410.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7975.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Risk of malignancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7974.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">GENERAL ISSUES</span><span class="headingEndMark"> — </span>The adverse effects associated with tumor necrosis factor (TNF)-alpha inhibitors are potentially serious. However, these risks must be interpreted in the context of the potential benefits and of the adverse effects associated with conventional therapies for the treatment of immune-mediated diseases (eg, glucocorticoids, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>), which are also significant and, in many cases, greater.</p><p>Thus, the decision to use an anti-TNF-alpha agent must be an individual one, based upon the specific clinical features and unique risk profile of a given patient.</p><p>As background to the overview of adverse events associated with TNF-alpha inhibition, we provide a brief review of TNF-alpha biology and the role of this cytokine in host defense.</p><p>The adverse drug effect profile of anti-TNF-alpha inhibitors may differ based on the condition being treated [<a href="#rid1">1</a>]. In a comparison of two prospective safety cohorts of patients with rheumatoid arthritis (RA) and psoriasis, there was a much lower rate of adverse/mortality events in subjects with psoriasis (124) compared with RA (1248; multivariate incidence rate ratio, 0.6 [95% CI 0.5-0.7]). Patients with RA had higher rates of infections, cardiac/respiratory disorders, and infusion reactions (higher use of <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>), while those with psoriasis had more skin/subcutaneous and hepatobiliary disorders. The differences persisted after correction for sex, age (the RA group was older), treatment, concomitant disease, hypertension, diabetes (more in the psoriasis group), hypercholesterolemia (more in the psoriasis group), and simultaneous therapy with <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, and after excluding patients receiving glucocorticoids (RA 41.3 percent versus psoriasis 0.2 percent).</p><p class="headingAnchor" id="H3"><span class="h2">TNF-alpha biology</span><span class="headingEndMark"> — </span>TNF-alpha is synthesized initially by activated macrophages and T cells as a transmembrane precursor protein. The cytoplasmic tail of this protein is then cleaved to release soluble TNF-alpha. The biologic activity of TNF-alpha requires the aggregation of three TNF-alpha monomers to form trimeric TNF-alpha, which then acts by binding to one of two types of receptors: TNFR1 or TNFR2 [<a href="#rid2">2,3</a>]. TNFR1 and TNFR2 are also known as p55 and p75, respectively. The trimeric structure of the receptors mimics that of the active cytokine [<a href="#rid4">4</a>].</p><p>TNFR1 and TNFR2 both exert multiple effects on the immune system, including the following [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Stimulation of the release of the inflammatory cytokines interleukin (IL)-1beta, IL-6, IL-8, and granulocyte macrophage colony-stimulating factor (GM-CSF)</p><p class="bulletIndent1"><span class="glyph">●</span>Upregulation of the expression of endothelial adhesion molecules (ICAM-1, VCAM-1, E-selectin) and chemokines (MCP-1, MIP-2, RANTES and MIP-1alpha)</p><p class="bulletIndent1"><span class="glyph">●</span>Coordination of the migration of leukocytes to targeted organs</p><p></p><p class="headingAnchor" id="H3878954948"><span class="h2">TNF-alpha and host defenses</span><span class="headingEndMark"> — </span>TNF-alpha is important for macrophage activation, phagosome activation, differentiation of monocytes into macrophages, recruitment of neutrophils and macrophages, granuloma formation, and maintenance of granuloma integrity [<a href="#rid6">6</a>]. The effects of TNF-alpha on infection have been examined in animal experiments, including models that utilize neutralizing antibodies, disrupt transcription of the gene for TNF-alpha or one of its receptors, or lead to the overexpression of soluble TNF-alpha receptor [<a href="#rid7">7-12</a>].</p><p>Animal experiments have demonstrated the importance of TNF-alpha in protection against several pathogens including Mycobacterium tuberculosis, M. avium, M. bovis, Bacillus Calmette-Guérin (BCG), <em>Aspergillus fumigatus</em>, <em>Histoplasma capsulatum</em>, <em>Toxoplasma gondii</em>, <em>Cryptococcus neoformans</em>, and <em>Candida albicans</em> [<a href="#rid8">8,10,13-15</a>]. These organisms are not killed readily by host defense mechanisms but rather are sequestered within granulomas, which are comprised of a central core of macrophages, multinucleated giant cells, and necrotic debris surrounded by macrophages and lymphocytes [<a href="#rid16">16</a>]. TNF-alpha is required for the orderly recruitment of these cells and for continued maintenance of the granuloma structure [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H5"><span class="h2">TNF-alpha antagonists</span><span class="headingEndMark"> — </span>Five inhibitors of TNF-alpha are approved for the treatment of a variety of inflammatory illnesses (eg, RA, Crohn disease) by the US Food and Drug Administration (FDA). These medications are:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">Etanercept</a> – A soluble p75 TNF-alpha receptor fusion protein</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">Infliximab</a> – A chimeric (mouse/human) anti-TNF-alpha antibody</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">Adalimumab</a> – A fully human monoclonal anti-TNF-alpha antibody</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8644" href="/d/drug information/8644.html" rel="external">Certolizumab pegol</a> – An antigen-binding fragment (Fab') of a humanized monoclonal antibody coupled to polyethylene glycol</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">Golimumab</a> – A human anti-TNF-alpha monoclonal antibody</p><p></p><p><a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">Infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>, and <a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">golimumab</a> are monoclonal antibodies. <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">Etanercept</a> is a soluble, bivalent TNF-alpha receptor. <a class="drug drug_general" data-topicid="8644" href="/d/drug information/8644.html" rel="external">Certolizumab pegol</a> is the antigen-binding fragment (Fab') of a humanized monoclonal antibody coupled to polyethylene glycol. Highly similar forms of some of these molecules, termed "biosimilars" are now being tested or have been licensed for use in some countries. A "biosimilar" is defined by the World Health Organization (WHO) as a "biotherapeutic product which is similar in terms of quality, safety and efficacy to an already licensed reference biotherapeutic product" [<a href="#rid18">18</a>]; "similarity" is defined as the "absence of a relevant difference in the parameter of interest." Biosimilar TNF-alpha inhibitors are thought to have similar efficacy and adverse event profiles for the treatment of RA when compared with originator TNF-alpha inhibitors [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases", section on 'TNF inhibition'</a>.)</p><p class="headingAnchor" id="H6"><span class="h3">Monoclonal antibodies</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">Infliximab</a> and <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> both bind monomeric and trimeric TNF-alpha. Infliximab is a chimeric antibody with human constant region of immunoglobulin G (IgG)1 coupled to the variable regions of mouse anti-TNF-alpha. By contrast, adalimumab is a human monoclonal antibody comprised of the human constant region of IgG1 attached to human variable regions. Adalimumab is, therefore, a fully human monoclonal antibody. <a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">Golimumab</a> is a human IgG1 kappa monoclonal antibody specific for human TNF-alpha that binds to both the soluble and transmembrane bioactive forms of human TNF-alpha.</p><p class="headingAnchor" id="H7"><span class="h3">Soluble fusion protein</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">Etanercept</a> is a fusion protein consisting of two TNFR2 coupled to the constant region of human IgG1. In contrast to <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> and <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>, etanercept binds not only to trimeric TNF-alpha but also to lymphotoxin, a cytokine once known as TNF-beta whose characteristics overlap those of TNF-alpha.</p><p class="headingAnchor" id="H8"><span class="h3">Pegylated Fab' fragment</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8644" href="/d/drug information/8644.html" rel="external">Certolizumab pegol</a> (formerly CDP870) is a covalently bonded construct consisting of an antigen-binding portion of a monoclonal antibody (Fab' fragment) covalently bonded to polyethylene glycol. The addition of polyethylene glycol may reduce the antigenicity and prolong the half-life of this anti-TNF-alpha agent. In contrast to <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> and <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>, certolizumab does not contain an Fc portion and therefore does not induce complement activation, antibody-dependent cellular cytotoxicity, or apoptosis. The full impact of this structural change on the efficacy of the agent is not clear. Certolizumab is designed to be administered on an every-other-week basis by subcutaneous administration.</p><p class="headingAnchor" id="H26921170"><span class="h3">Therapeutic differences</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">Infliximab</a> and <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> both have been approved for a broader clinical spectrum of activity than <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>. For example, the former medications are effective in many cases of inflammatory bowel disease (IBD), uveitis, and sarcoidosis as well as RA, psoriatic arthritis, and the seronegative spondyloarthropathies [<a href="#rid20">20</a>]. In contrast, etanercept does not appear to be effective in IBD, uveitis, or sarcoidosis [<a href="#rid21">21,22</a>]. <a class="drug drug_general" data-topicid="8644" href="/d/drug information/8644.html" rel="external">Certolizumab pegol</a>, which first received regulatory approval for use in Crohn disease, is now available for use in rheumatoid and psoriatic arthritis and ankylosing spondylitis/spondyloarthropathies in many countries.</p><p class="headingAnchor" id="H9"><span class="h1">ADVERSE EFFECTS</span></p><p class="headingAnchor" id="H10"><span class="h2">Injection site reactions</span><span class="headingEndMark"> — </span>Skin reactions characterized by itching, pain, redness, irritation, bruising, or swelling at the site of medication injection are common but usually minor problems with subcutaneously administered agents (eg, <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>, <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">golimumab</a>, and <a class="drug drug_general" data-topicid="8644" href="/d/drug information/8644.html" rel="external">certolizumab pegol</a>) [<a href="#rid23">23</a>]. Such injection site reactions (ISR) typically occur during the first month of treatment and last for three to five days. They can usually be managed, if needed, with measures including local cold packs, topical corticosteroids, and analgesia, and by varying the injection site; discontinuation of the medication is required in only a small number of patients. ISR generally do not prevent continued therapy. Estimated frequencies of ISR vary. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In one trial involving <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> with concomitant <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, ISR were reported in 9 percent of patients and were most often characterized by erythema, pain, pruritus, other nonspecified reactions, and hematomas (in 4, 2, 2, 1, and 1 percent of patients, respectively) [<a href="#rid24">24</a>]. Most reactions were mild, and injections were discontinued in only three patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cumulative incidence of ISR in a six-month study of <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> was 37 percent [<a href="#rid25">25</a>] but has been lower in some other trials. For example, in a trial comparing originator etanercept (Enbrel) with a biosimilar etanercept (SB4), ISR were more frequent in patients receiving the originator biologic (156 ISR in 51 patients [17 percent] versus 22 ISR in 11 patients [4 percent]) [<a href="#rid26">26</a>]. Most were mild and within two to eight weeks of commencing therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Trials of <a class="drug drug_general" data-topicid="8644" href="/d/drug information/8644.html" rel="external">certolizumab pegol</a> and <a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">golimumab</a> reported injection and/or infusion site reactions in between 1 and 7.5 percent of patients [<a href="#rid27">27-29</a>].</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Infusion reactions</span><span class="headingEndMark"> — </span>Infusion reactions with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> are classified as one of two types:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute – Acute reactions are those that occur within 24 hours. Such reactions usually occur between 10 minutes and four hours after the start of the infusion.</p><p class="bulletIndent1"><span class="glyph">●</span>Delayed – Delayed reactions develop between 1 and 14 days after the start of treatment but typically occur after five to seven days.</p><p></p><p>Both acute and delayed infusion reactions can be characterized further as mild, moderate, or severe, depending upon the accompanying signs and symptoms. Approximately 90 percent of infusion reactions that occur with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> are acute [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H12"><span class="h3">Acute infusion reactions</span><span class="headingEndMark"> — </span>Acute infusion reactions sometimes represent true allergies, ie, immunoglobulin E (IgE)-mediated type I (anaphylactic) reactions that include hypotension, bronchospasm, wheezing, and/or urticaria [<a href="#rid31">31,32</a>]. (See  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a>.)</p><p>True anaphylactic reactions occur in some patients treated with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> [<a href="#rid33">33</a>]. However, the great majority of acute infusion reactions that occur with infliximab treatment are characterized more by nonspecific symptoms and are classified more accurately as anaphylactoid (nonallergic) reactions [<a href="#rid31">31</a>]. These reactions are not mediated by IgE. (See  <a class="medical medical_review" href="/d/html/2086.html" rel="external">"Drug hypersensitivity: Classification and clinical features"</a>.)</p><p>Acute, IgE-mediated infusion reactions to <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> are uncommon. In a cohort study of 165 patients receiving infliximab, some type of infusion reaction occurred in 16 patients (10 percent); reactions were mostly mild to moderate in severity (mild, moderate, and severe reactions in 3, 1, and 1 percent of infusions, respectively) [<a href="#rid30">30</a>]. While it was difficult to fully define the nature of the infusion reactions, IgE-mediated anaphylactic reactions were thought to be less likely since the reactions were generally managed successfully by reducing the rate of infusion. Furthermore, both serum tryptase and serum IgE levels were normal in all six patients in whom they were measured [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H13"><span class="h3">Delayed infusion reactions</span><span class="headingEndMark"> — </span>Delayed infusion reactions resemble serum sickness in the timing of their onset and their association with skin rash, diffuse joint pains, myalgias, and fatigue, sometimes accompanied by fever. Delayed reactions may represent mild type III (immune complex-mediated) reactions. (See  <a class="medical medical_review" href="/d/html/2078.html" rel="external">"Serum sickness and serum sickness-like reactions"</a>.)</p><p>A large observational study using United States Medicare data evaluated the frequency of these hypersensitivity reactions (HSRs) among patients with rheumatoid arthritis (RA) receiving <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">abatacept</a>, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a>, <a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">golimumab</a> by infusion, and injected biologic agents [<a href="#rid34">34</a>]. From 725,591 biologic agent administrations, they identified 248 HSRs among 80,587 new users of biologic agents. Over six months, the cumulative incidence was low (&lt;1 percent), with incidence ratios ranging from 2.4 (abatacept) to 239.5 (rituximab) per 10<sup>6</sup> person-days. After adjustment, rituximab, infliximab, abatacept, and tocilizumab infusions were associated with a higher risk of HSR when compared with injectable anti-TNF inhibitors.</p><p class="headingAnchor" id="H14"><span class="h3">Prevention</span><span class="headingEndMark"> — </span>A variety of strategies are helpful in preventing <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> infusion reactions. Through the use of such strategies, infliximab can usually be readministered even to patients who have previously experienced severe (non-anaphylactic) reactions.</p><p>Preventive strategies include [<a href="#rid30">30</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Premedication 90 minutes prior to the infusion with <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> (650 mg) and an antihistamine (eg, 25 to 50 mg of <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> or 10 mg of <a class="drug drug_general" data-topicid="9236" href="/d/drug information/9236.html" rel="external">cetirizine</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of a test dose of <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>. The test dose begins at a rate of 10 mL/hour, followed by an increase of the infusion rate as tolerated every 15 minutes until the usual rate of 125 mL/hour is reached.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with a history of anaphylaxis after <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (50 mg every eight hours) should be given over the 24 hours prior to infliximab infusion, in addition to <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> and <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>.</p><p></p><p>The coadministration of <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> or <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> appears to reduce the risk of infusion reactions, probably through an effect on drug immunogenicity [<a href="#rid33">33</a>]. Strategies designed to combat the effects of antibodies that some patients develop to infliximab are presented elsewhere. (See  <a class="medical medical_review" href="/d/html/7974.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases"</a>.)</p><p class="headingAnchor" id="H15"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>As noted above, the vast majority of acute infusion reactions that occur with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> are not mediated by IgE and are not anaphylactic. The approach to treatment depends upon whether the reaction is graded as mild, moderate, or severe  (<a class="graphic graphic_table graphicRef85654" href="/d/graphic/85654.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef85655" href="/d/graphic/85655.html" rel="external">algorithm 1</a>) [<a href="#rid35">35</a>]. Many reactions respond to stopping the infusion temporarily and providing hydration, <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>, and <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>.</p><p>Delayed infusion reactions to <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> can usually be treated with the combination of <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> (650 mg four times daily) and an antihistamine, either <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> (50 mg daily or twice daily) or a second-generation antihistamine (eg, <a class="drug drug_general" data-topicid="9572" href="/d/drug information/9572.html" rel="external">loratadine</a> 10 mg daily).</p><p class="headingAnchor" id="H26921246"><span class="h2">Cytopenias</span><span class="headingEndMark"> — </span>Neutropenia may occur in patients on tumor necrosis factor (TNF)-alpha inhibitors but is usually mild; other cytopenias are uncommon [<a href="#rid36">36</a>]. Pancytopenia and aplastic anemia are rare [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H26921253"><span class="h3">Neutropenia</span><span class="headingEndMark"> — </span>A decrease in the number of peripheral blood neutrophils is common in patients who receive TNF-alpha inhibitors [<a href="#rid36">36</a>]. Neutropenia, defined as less than 2 X 10<sup>9</sup> cells/L, occurred during treatment with these medications in 19 percent of 367 patients with inflammatory arthritis [<a href="#rid36">36</a>]. Levels of less than 1.5 X 10<sup>9</sup>/L were seen in 9 percent. The mechanism by which neutropenia occurs on these medications has not been defined.</p><p>The risk of neutropenia was significantly higher in patients with a past history of neutropenia while receiving other disease-modifying antirheumatic drugs (DMARDs; hazard ratio [HR] 3, 95% CI 1.7-5.3). Patients with neutropenia also had significantly lower baseline neutrophil counts compared with those who did not (4.2 X 10<sup>9</sup>/L , 95% CI 3.8-4.6, versus 6.2 X 10<sup>9</sup>/L, 95% CI 6.0-6.5). Similar findings were seen regardless of the clinical response to treatment and whether or not patients were also receiving <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>.</p><p>A decrease in neutrophils was seen in 74 percent of patients after two weeks of therapy (mean decrease in neutrophil counts of 1.1 X 10<sup>9</sup>/L, 95% CI 0.9-1.3). Other white cell subsets, including lymphocytes, monocytes, and basophils, tended to increase (0.3, 0.6, and 0.1 X 10<sup>9</sup>/L, respectively).</p><p>Most patients with neutropenia did not require discontinuation of therapy, but persistence or recurrence was often seen in those switched to another TNF-alpha inhibitor. Serious infections occurred in 6 percent (4 of 69) of the patients who experienced neutropenia (less than 2 X 10<sup>9</sup>/L). Less than 1 percent (three) of all patients in the cohort developed a neutrophil count less than 0.5 X 10<sup>9</sup>/L.</p><p>Because of the risk of neutropenia among patients treated with TNF-alpha inhibitors, it is appropriate to check a complete blood count within one month of starting one of these agents and then to repeat this test every three to six months, assuming that the patient’s white blood cell count is stable.</p><p class="headingAnchor" id="H16"><span class="h2">Infection</span><span class="headingEndMark"> — </span>TNF-alpha is an important component of the immune system's response to a variety of infections, and use of TNF-alpha inhibitors has been associated with an increased risk of serious infections. These include bacterial infections (particularly pneumonia), zoster, tuberculosis, and opportunistic infections. (See  <a class="medical medical_review" href="/d/html/1410.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections"</a> and  <a class="medical medical_review" href="/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors"</a>.)</p><p>Screening for latent tuberculosis infection should be performed before the initiation of TNF-alpha inhibitor therapy because of the increased risk of reactivation of latent tuberculosis. Patients with evidence of latent tuberculosis should initiate treatment for latent tuberculosis before starting a TNF-alpha inhibitor. The appropriate timing for starting a TNF-alpha inhibitor in such patients is discussed separately. (See  <a class="medical medical_review" href="/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors", section on 'Screening'</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Demyelinating disease</span><span class="headingEndMark"> — </span>A potential link between TNF-alpha inhibitors and demyelinating disease has been suggested but not proven [<a href="#rid38">38,39</a>]. Although a causal relationship between TNF-alpha inhibitors and demyelinating disease remains uncertain, anti-TNF-alpha agents should generally be avoided in patients with established diseases that are associated with demyelination, such as multiple sclerosis (MS); in addition, anti-TNF-alpha therapy should be discontinued immediately in any patient with suspected demyelination. Some RA experts are also cautious about using TNF-alpha inhibitors in patients with family histories of MS. (See  <a class="medical medical_review" href="/d/html/1688.html" rel="external">"Evaluation and diagnosis of multiple sclerosis in adults"</a> and  <a class="medical medical_review" href="/d/html/1687.html" rel="external">"Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults"</a>.)</p><p>Concern regarding demyelination or the exacerbation of intercurrent demyelinating diseases in patients treated with TNF-alpha inhibitors stems from the use of a TNF-alpha inhibitor prototype, lenercept, in MS. Lenercept, a recombinant TNF-alpha receptor p55-immunoglobulin fusion protein (sTNFR-IgG p55), was halted in clinical testing because of concerns related to adverse effects. In a clinical trial of 168 MS patients, those treated with lenercept had more frequent and severe exacerbations of MS than did the patients taking placebo [<a href="#rid39">39</a>].</p><p>With regard to TNF-alpha inhibitors approved by the US Food and Drug Administration (FDA), a 2001 review of cases of demyelinating disease in the FDA database revealed 19 associated with the use of these agents, 17 with <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> and 2 with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> [<a href="#rid40">40</a>]. <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">Adalimumab</a>, <a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">golimumab</a>, and <a class="drug drug_general" data-topicid="8644" href="/d/drug information/8644.html" rel="external">certolizumab pegol</a> had not been approved for clinical use at that time.</p><p>The following findings were reported [<a href="#rid40">40</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms of demyelination included confusion, ataxia, dysesthesia, and paresthesia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic findings included facial nerve palsy, optic neuritis, hemiparesis, transverse myelitis, and ascending motor neuropathy consistent with the Guillain-Barré syndrome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Magnetic resonance imaging findings suggestive of demyelination were present in the brain or spinal cord in most patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All neurologic events had a temporal relationship to anti-TNF-alpha therapy, and all improved partially or completely upon discontinuation of such therapy. One patient who had anti-TNF-alpha therapy reintroduced experienced a recurrence of symptoms.</p><p></p><p>During the time that the 17 cases of demyelinating disease associated with <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> use were reported, 77,152 patients received etanercept therapy, representing a total of 55,313 patient-years [<a href="#rid40">40</a>]. The incidence of demyelinating disease in patients receiving etanercept was 31 per 100,000 patient-years of exposure, compared with 4 to 6 per 100,000 per year for the general population.</p><p>Similarly, optic neuritis has been reported in association with the use of <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>, <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, and <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> [<a href="#rid41">41</a>]. Demyelinating peripheral nervous system disease has also been reported with these drugs [<a href="#rid42">42,43</a>]. In a cohort study using large United States healthcare databases, cases of optic neuritis were rare in patients on TNF inhibitors, with similar crude rates among anti-TNF and nonbiologic DMARD-treated groups (4.5 and 5.4 per 100,000 person-years, respectively) [<a href="#rid44">44</a>].</p><p>By contrast, linkage of the large DANBIO inflammatory arthritis cohort in Denmark with a national MS database reported eight incident MS cases that occurred during 113,527 person-years of therapy in the cohort receiving anti-TNF-alpha therapy [<a href="#rid45">45</a>]. When compared with inflammatory arthritis patients never receiving anti-TNF-alpha therapy (four cases), an increased risk of MS was observed in males, (standardized incidence ratio [SIR] 3.5; 95% CI 1.5–8.4) and in patients with ankylosing spondylitis (who were predominantly male; SIR 3.9; 95% CI 1.5–10.4), with an overall cohort SIR of 1.1 (95% CI 0.6–2.0). The number of cases is small and might under-report demyelination cases that do not enter the MS registry. A<strong> </strong>collaborative observational study across five Nordic rheumatology registers of<strong> </strong>patients taking TNF inhibitor therapy confirmed the higher incidence of neuroinflammatory disease including multiple sclerosis in patients with spondyloarthritis compared with those with RA, which did not vary based on whether patients were taking monoclonal antibody TNF-alpha antagonists versus <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H18"><span class="h2">Heart failure</span><span class="headingEndMark"> — </span>Targeted TNF-alpha inhibitor use may be associated with heart failure (HF), although the data are mixed. Concern about this possible adverse effect stems from randomized trials of TNF-alpha inhibitors as a potential therapy for HF and from early postmarketing surveillance data gathered by the FDA [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H930091004"><span class="h3">Overview</span><span class="headingEndMark"> — </span>Data regarding the risk of HF with the use of TNF-alpha inhibitors at the FDA-approved doses are inconclusive [<a href="#rid48">48</a>]. However, the labels of <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>, <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, and <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> contain the following disease-related concern: "Use with caution in patients with HF or decreased left ventricular function; worsening and new-onset HF has been reported." In addition, infliximab is contraindicated at doses higher than 5 mg/kg in patients with moderate or severe HF (New York Heart Association [NYHA] class III/IV)  (<a class="graphic graphic_table graphicRef52683" href="/d/graphic/52683.html" rel="external">table 2</a>). The <a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">golimumab</a> and <a class="drug drug_general" data-topicid="8644" href="/d/drug information/8644.html" rel="external">certolizumab pegol</a> labels include similar wording.</p><p>Given the evidence to date, in patients with symptomatic HF, we suggest that treatment strategies other than TNF-alpha inhibitors should be employed. In a patient who develops HF while on a TNF-alpha inhibitor, a drug-induced cause should be suspected, and use of the medication should be suspended.</p><p>For patients with RA and mild (NYHA functional class I or II)  (<a class="graphic graphic_table graphicRef52683" href="/d/graphic/52683.html" rel="external">table 2</a>) HF whose arthritis is refractory to other DMARDs or biologic agents, targeted TNF-alpha inhibition might be considered. If the use of anti-TNF-alpha treatment is entertained, we suggest the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiology consultation</p><p class="bulletIndent1"><span class="glyph">●</span>Baseline echocardiography with ejection fraction</p><p class="bulletIndent1"><span class="glyph">●</span>Close follow-up</p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of high TNF-alpha inhibitor doses (eg, more than <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> 3 mg/kg, <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> 40 mg every two weeks, or <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> 50 mg/week)</p><p class="bulletIndent1"><span class="glyph">●</span>Prompt discontinuation of anti-TNF-alpha therapy if HF worsens</p><p></p><p>Despite concerns, the risk of HF remains uncertain, and other studies have suggested that patients with RA receiving TNF inhibitors have an overall decrease in the incidence of cardiovascular events compared with those receiving nonbiologic DMARD therapies [<a href="#rid49">49,50</a>]. In a study of 18,754 patients with RA who had 1801 cardiovascular disease (CVD) events (myocardial infarction, stroke, heart failure, and CVD-related death validated from hospital/death records), TNF-alpha inhibitors and <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">abatacept</a> were associated with a decreased risk of CVD compared with conventional synthetic DMARDs (HR 0.81, 95% CI 0.71-0.93; and HR 0.50, 95% CI 0.30-0.83, respectively) [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H19"><span class="h3">Clinical trials in heart failure</span><span class="headingEndMark"> — </span>Clinical trials of both <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> and <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> were performed with the hypothesis that TNF-alpha inhibition would improve cardiac function in patients with HF [<a href="#rid52">52-54</a>]. Two major randomized, placebo-controlled trials evaluated etanercept as a possible therapy HF: the RENAISSANCE trial (925 pts) and the RECOVER trial (1123 pts) [<a href="#rid52">52,53</a>].</p><p>In the combined analysis of these two trials (ie, RENEWAL), <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> was found to have no effect on the death or chronic HF hospitalization end point. The relative risk for etanercept-treated patients was 1.1 (95% CI 0.9-1.3). On the basis of prespecified stopping rules, both trials were terminated prematurely because of futility. In addition to excluding any clinically relevant benefit of etanercept on the rate of death or hospitalization due to chronic HF, RENEWAL also raised concerns about the possible exacerbation of HF in some patients treated with TNF-alpha inhibitors.</p><p>These concerns were confirmed in a trial involving <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> as a therapy for HF, known as the ATTACH trial [<a href="#rid54">54</a>]. In this trial, the major inclusion criteria were NYHA class III or IV HF  (<a class="graphic graphic_table graphicRef52683" href="/d/graphic/52683.html" rel="external">table 2</a>) and a left ventricular ejection fraction less than 35 percent. One hundred and fifty patients were divided into three treatment groups: placebo, infliximab 5 mg/kg, and infliximab 10 mg/kg. After induction therapy, no further infliximab was given; patients were followed for one year. An analysis of all-cause mortality at one year showed eight deaths (16 percent) in the infliximab 10 mg/kg group, compared with four (8 percent) in both the infliximab 5 mg/kg and placebo groups.</p><p class="headingAnchor" id="H20"><span class="h3">FDA reports of heart failure</span><span class="headingEndMark"> — </span>The FDA published a summary of 47 cases of HF associated with <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> or <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> reported to the Adverse Events Response System (AERS) through February, 2002 [<a href="#rid47">47</a>]. Thirty-eight of these patients developed new-onset HF, and nine experienced an HF exacerbation.</p><p>Among the 38 patients with new-onset HF, 19 had no identifiable risk factors such as coronary artery disease, hypertension, history of myocardial infarction, or diabetes, and 10 were under the age of 50 years. After TNF-alpha inhibition was discontinued and therapy for HF began, 3 of these 10 patients had complete resolution of HF, six improved, and one died.</p><p class="headingAnchor" id="H21"><span class="h3">Adalimumab and heart failure</span><span class="headingEndMark"> — </span>Because of the adverse experiences reported with <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> and <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> with regard to HF, no treatment trials of <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> in HF have ever been attempted but a review of the safety of adalimumab in global clinical trials was released by the manufacturer [<a href="#rid55">55</a>]. Among 10,050 patients with RA of at least three years' duration who had a total of 12,066 patient-years of exposure to adalimumab, the event rate of HF was 0.26 per 100 patient-years. The HF event rate in 542 patients with less than three years of RA and 917 patient-years of exposure was 0.11 per 100 patient-years. A lower HF event rate (0.05 per 100 patient-years) was noted in an analysis of United States postmarketing safety of adalimumab with 55,384 patient-years of exposure from 2002 to 2004 [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H22"><span class="h3">Registry data and cohort studies</span><span class="headingEndMark"> — </span>Data from a registry of patients with rheumatic disease suggested that RA is associated with an increased risk of HF, but that this risk might be attenuated by TNF inhibition [<a href="#rid57">57</a>]. A two-year study of nearly 16,000 patients with either RA or osteoarthritis reported that HF was more common among patients with RA than those with osteoarthritis (3.9 versus 2.3 percent), even after adjustment for differences in baseline demographic characteristics. However, HF was less common among RA patients treated with TNF inhibitors (3.1 versus 3.8 percent), even after adjustments for baseline HF risk factors.</p><p>A subsequent study of 20,243 patients from four different healthcare benefit cohorts in the United States, which compared HF risk in new users of TNF inhibitors with new users of nonbiologic (synthetic) DMARDs (with similar baseline covariates), found no significant increase in the risk of either new or recurrent HF in the patients begun on a TNF inhibitor [<a href="#rid58">58</a>]. Oral glucocorticoid use was associated with a dose-dependent increase in the risk of HF, which was seen in patients receiving at least 5 mg daily of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (HR 1.54, 95% CI 1.09-2.19), but glucocorticoid use did not modify the risk with TNF inhibitors. Subgroup analysis found elevated risk in patients who initiated TNF inhibitor therapy before 2002 (HR 2.17, 95% CI 0.45-10.50, test for interaction p = 0.036). The reasons for the increased risk prior to 2002 are uncertain, but in October 2001 a warning was issued regarding HF and TNF inhibitors, and it is possible that patients thought by their treating clinicians to be at increased risk of heart failure were then disproportionately not treated with a TNF inhibitor, resulting subsequently in a lower rate of adverse events.</p><p>Additionally, in a cross-sectional study of patients with RA compared with age- and sex-matched controls, the prevalence of HF was not significantly different between patients treated with nonbiologic DMARDs and TNF inhibitors, or other biologic DMARDs (25, 22, and 27 percent, respectively) [<a href="#rid59">59</a>]. Likewise, a cohort of Veterans Administration patients with RA and without RA compared with a similar group who had received anti-TNF therapy showed no difference among the groups in either HF exacerbation or mortality [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H24"><span class="h2">Pulmonary disease</span><span class="headingEndMark"> — </span>TNF inhibitors have been used for the treatment of various lung diseases and for systemic inflammatory rheumatic disorders with or without pulmonary manifestations. Adverse effects on the lung have included [<a href="#rid61">61</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Granulomatous disease – There are a number of case reports of sarcoid-like disease; discontinuation of the TNF inhibitor with or without a course of glucocorticoids generally led to resolution of symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary fibrosis/interstitial lung disease – Studies have reported pulmonary fibrosis and/or interstitial lung disease (ILD) in patients taking TNF-alpha inhibitors. Notably, most of these patients had RA, many had a background of pulmonary disease (especially ILD), and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> use was common (which can also be associated with hypersensitivity pneumonitis). ILD appears to have a poorer prognosis than granulomatous disease; some patients die of pulmonary fibrosis. In one study, patients with RA and pre-existing ILD who were receiving TNF inhibitor therapy had similar mortality rates to RA patients with ILD receiving nonbiologic DMARDs [<a href="#rid62">62</a>]. However, more patients receiving TNF inhibitor therapy had the cause of death attributed to ILD, although reporting bias could not be excluded.</p><p></p><p class="headingAnchor" id="H25"><span class="h2">Hepatotoxicity</span><span class="headingEndMark"> — </span>The risk of hepatotoxicity associated with TNF-alpha inhibitors appears to be small. In January 2004, at least 35 postmarketing reports of severe hepatic reactions had been received by the FDA, leading to a warning to health care professionals [<a href="#rid63">63</a>]. Various types of hepatic involvement have been noted, including acute liver failure, hepatitis, and cholestasis. Fatal liver disease and cases requiring liver transplantation have been reported. The mechanisms involve drug-induced liver injury (DILI), cholestatic liver injury, and autoimmune liver disease. </p><p>Subsequent reviews have further indicated that this rare adverse event may vary according to the disease being treated as well as the type of TNF-alpha inhibitor [<a href="#rid64">64</a>]. Most reports of serious liver outcomes pertain to <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, often when used at higher doses for Crohn disease. The drug label for all TNF-alpha inhibitor medications carries a warning about the possibility of severe hepatic reactions, with jaundice or marked increase in serum alanine or aminotransferases. </p><p>The largest study, involving 6861 patients with RA treated with TNF-alpha inhibitors, noted alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels &gt;1 times upper limit of normal (ULN) in 17.6 percent of patients, and &gt;2 times ULN in 2.1 percent, most of which were not persistent and did not result in change of therapy [<a href="#rid65">65</a>]. Higher levels, &gt;3 or 5 times ULN, were found in 0.57 and 0.13 percent of cases, respectively (ie, 48 patients, of whom only 5 had pre-existing liver disease). Abnormal liver function tests (LFTs) were increased in those taking concomitant <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> and <a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">leflunomide</a>. <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">Infliximab</a> was more likely than <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> to be related, and <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> showed no increase compared with patients receiving conventional DMARD therapy.</p><p>Compared with RA, other types of arthritis such as psoriatic arthritis are associated with higher rates of concomitant liver disease and may also have higher rates of TNF-alpha inhibitor-induced autoimmune liver disease. A report from Korea found that 23.7 percent of patients (86 out of 363) receiving TNF-alpha inhibitors for ankylosing spondylitis followed for a mean of 3.7 years showed abnormal LFT on two consecutive tests, most one to two times ULN, with 15 percent &gt;3 times ULN [<a href="#rid66">66</a>]. Patients with higher ALT levels were found to have liver disease such as nonalcoholic fatty liver disease. Most patients continued TNF-alpha inhibitors, with LFT changes reverting to normal, followed by subsequent elevation, even in 9 of 13 who changed TNF-alpha inhibitors.</p><p>The use and risks of TNF inhibitors in patients with viral hepatitis, including hepatitis B and C, are described separately. (See  <a class="medical medical_review" href="/d/html/1410.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections", section on 'Viral infections'</a> and  <a class="medical medical_review" href="/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p class="headingAnchor" id="H27"><span class="h2">Cutaneous reactions</span></p><p class="headingAnchor" id="H28"><span class="h3">Psoriatic skin lesions</span><span class="headingEndMark"> — </span>Psoriasiform skin lesions (termed paradoxical psoriasis) can be induced by anti-TNF-alpha therapy [<a href="#rid67">67-71</a>]. A 2010 systematic literature review identified 207 cases in which psoriatic skin lesions developed in patients treated with a variety of anti-TNF-alpha agents for one of several indications, including RA, spondyloarthritis, inflammatory bowel disease (IBD), and psoriatic arthritis. Pustular psoriasis was common, although all forms were reported [<a href="#rid72">72</a>]. Partial or complete resolution occurred with psoriasis treatment in most patients, with 66 percent of cases continuing treatment with an anti-TNF-alpha agent. Although one study reported a higher incidence of psoriatic lesions with <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> compared with other TNF-alpha inhibitors [<a href="#rid67">67</a>], this finding has not been confirmed by other reports [<a href="#rid68">68</a>].</p><p>The pathogenesis of psoriatic skin lesions may involve unopposed production of interferon-alpha by skin plasmacytoid dendritic cells as a result of changes in cytokine balance [<a href="#rid72">72</a>]. A single-center report suggests that TNF inhibitor-induced paradoxical psoriasis skin biopsies might have certain differences with idiopathic psoriasis skin biopsies, which may assist in differentiating the two conditions [<a href="#rid71">71</a>].</p><p class="headingAnchor" id="H1496760020"><span class="h3">Other dermatologic conditions</span><span class="headingEndMark"> — </span>A variety of other dermatologic conditions have been reported in association with TNF-alpha inhibitors. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Injection site and infusion reactions (see <a class="local">'Injection site reactions'</a> above and <a class="local">'Infusion reactions'</a> above)</p><p class="bulletIndent1"><span class="glyph">●</span>Cutaneous viral (eg, herpes zoster and varicella), bacterial, and fungal infections (see <a class="local">'Infection'</a> above)</p><p class="bulletIndent1"><span class="glyph">●</span>Eczematous dermatitis [<a href="#rid73">73</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Cutaneous manifestations of systemic lupus erythematosus (see  <a class="medical medical_review" href="/d/html/7974.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases", section on 'Systemic lupus erythematosus'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Leukocytoclastic vasculitis (see  <a class="medical medical_review" href="/d/html/7974.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases", section on 'Vasculitis'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Lichen planus and lichen planus-like eruptions [<a href="#rid74">74</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Rare possible alopecia [<a href="#rid75">75</a>]</p><p></p><p>The frequency of cutaneous adverse events (CAE) was evaluated in a study involving 5437 patients with chronic rheumatologic diseases who had 17,330 patient-years of exposure to TNF inhibitors (<a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>, and <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> in 46, 30, and 23 percent, respectively) [<a href="#rid76">76</a>]. A total of 920 CAE were identified (incidence rate [IR] per 1000 patient-years of 53). The most common CAE were infection, infusion reactions, autoimmune skin diseases, and skin malignancy (IR 28, 15, 5, and 3 per 1000 patient-years, respectively). A total of 89 serious CAE occurred (IR 5.1 per 1000 patient-years); drug discontinuation was common (32 percent of all patients and 53 percent of patients with any CAE).</p><p>Cutaneous lesions associated with TNF inhibitor therapy have been described in several studies of patients with IBD [<a href="#rid77">77-80</a>]. The largest of these involved a cohort of 917 consecutive patients with IBD on such therapy for a median of 3.5 years, in whom 264 (29 percent) developed skin lesions (12.4 per 100 patient-years) [<a href="#rid77">77</a>]. Specific cutaneous lesions included (from most to least common) psoriasiform eczema, eczema, xerosis cutis, palmoplantar pustulosis, and psoriasis (in 31, 24, 11, 5, and 4 percent, respectively); other abnormalities were present in an additional 26 percent of patients, including bacterial folliculitis, acne vulgaris, alopecia areata, and various other mostly infectious and inflammatory skin lesions. The majority were managed effectively by a dermatologist experienced in seeing such patients and without discontinuation of TNF inhibitor therapy. Limitations of the analysis and its generalizability included the lack of a control group and the early referral within one academic center for evaluation and treatment by a single dermatologist. Generally similar findings are seen in the different studies, although frequencies of specific types of skin lesions do vary between the reports.</p><p class="headingAnchor" id="H30"><span class="h2">Malignancy</span><span class="headingEndMark"> — </span>The risk of malignancy associated with the use of TNF-alpha inhibitors is presented separately. (See  <a class="medical medical_review" href="/d/html/7975.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Risk of malignancy"</a>.)</p><p class="headingAnchor" id="H31"><span class="h2">Autoimmunity and autoantibodies</span><span class="headingEndMark"> — </span>The risk of autoimmunity associated with the use of TNF-alpha inhibitors is presented separately. (See  <a class="medical medical_review" href="/d/html/7974.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases"</a>.)</p><p class="headingAnchor" id="H32"><span class="h2">Pregnancy and breastfeeding</span><span class="headingEndMark"> — </span>The risks and use of the TNF inhibitors during pregnancy and breastfeeding are described in detail separately. (See  <a class="medical medical_review" href="/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Tumor necrosis factor inhibitors'</a>.)</p><p class="headingAnchor" id="H54598728"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/120032.html" rel="external">"Society guideline links: Side effects of anti-inflammatory and anti-rheumatic drugs"</a>.)</p><p class="headingAnchor" id="H33"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General issues</strong> – Tumor necrosis factor (TNF)-alpha is an inflammatory cytokine that plays an important role in host defense. Various types of TNF-alpha antagonists are available for clinical use, including some biosimilar agents, and may differ in their construction (eg, monoclonal antibodies, soluble fusion proteins). (See <a class="local">'General issues'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The TNF-alpha inhibitors have multiple potential adverse events, which include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Injection site reactions</p><p class="bulletIndent2"><span class="glyph">•</span>Infusion reactions</p><p class="bulletIndent2"><span class="glyph">•</span>Neutropenia</p><p class="bulletIndent2"><span class="glyph">•</span>Infections</p><p class="bulletIndent2"><span class="glyph">•</span>Demyelinating disease</p><p class="bulletIndent2"><span class="glyph">•</span>Heart failure (HF)</p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary disease</p><p class="bulletIndent2"><span class="glyph">•</span>Hepatotoxicity</p><p class="bulletIndent2"><span class="glyph">•</span>Cutaneous reactions, including paradoxical psoriasis</p><p class="bulletIndent2"><span class="glyph">•</span>Malignancy</p><p class="bulletIndent2"><span class="glyph">•</span>Induction of autoimmunity</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infusion reactions</strong> – Infusion reactions with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> are classified as one of two types:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute – Acute reactions are those that occur within 24 hours. Such reactions usually occur between 10 minutes and four hours after the start of the infusion. Management of acute infusion reactions depends upon the severity. (See <a class="local">'Acute infusion reactions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Delayed – Delayed reactions develop between 1 and 14 days after the start of treatment, but typically occur after five to seven days. (See <a class="local">'Delayed infusion reactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Demyelinating disease</strong> – TNF-alpha inhibitors have been associated with the development or exacerbation of neurologic disorders associated with demyelination, such as multiple sclerosis (MS). Anti-TNF-alpha therapy should be discontinued immediately in any patient with suspected demyelination. Reported neurologic findings include confusion, ataxia, dysesthesia, paresthesia, facial nerve palsy, optic neuritis, hemiparesis, transverse myelitis, and ascending motor neuropathy. However, the true nature of this association (real or spurious) has not been established. (See <a class="local">'Demyelinating disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart failure</strong> – Targeted TNF-alpha inhibitor use may be associated with the development or exacerbation of HF. Patients with symptomatic HF should be treated with strategies other than TNF-alpha inhibitors. In a patient who develops HF while on a TNF-alpha inhibitor, a drug-induced cause should be suspected, and use of the medication should be suspended. (See <a class="local">'Heart failure'</a> above.)</p><p></p><p class="headingAnchor" id="H4055168994"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges John Stone, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">García-Doval I, Hernández MV, Vanaclocha F, et al. Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts. Br J Dermatol 2017; 176:643.</a></li><li><a class="nounderline abstract_t">Beutler B, Cerami A. The biology of cachectin/TNF--a primary mediator of the host response. Annu Rev Immunol 1989; 7:625.</a></li><li><a class="nounderline abstract_t">Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19:163.</a></li><li><a class="nounderline abstract_t">Zhang G. Tumor necrosis factor family ligand-receptor binding. Curr Opin Struct Biol 2004; 14:154.</a></li><li><a class="nounderline abstract_t">Roach DR, Bean AG, Demangel C, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002; 168:4620.</a></li><li><a class="nounderline abstract_t">Koo S, Marty FM, Baden LR. Infectious complications associated with immunomodulating biologic agents. Infect Dis Clin North Am 2010; 24:285.</a></li><li><a class="nounderline abstract_t">Kindler V, Sappino AP, Grau GE, et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56:731.</a></li><li><a class="nounderline abstract_t">Allendoerfer R, Deepe GS Jr. Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J Immunol 1998; 160:6072.</a></li><li><a class="nounderline abstract_t">Garcia I, Miyazaki Y, Marchal G, et al. High sensitivity of transgenic mice expressing soluble TNFR1 fusion protein to mycobacterial infections: synergistic action of TNF and IFN-gamma in the differentiation of protective granulomas. Eur J Immunol 1997; 27:3182.</a></li><li><a class="nounderline abstract_t">Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 2:561.</a></li><li><a class="nounderline abstract_t">Benini J, Ehlers EM, Ehlers S. Different types of pulmonary granuloma necrosis in immunocompetent vs. TNFRp55-gene-deficient mice aerogenically infected with highly virulent Mycobacterium avium. J Pathol 1999; 189:127.</a></li><li><a class="nounderline abstract_t">Bopst M, Garcia I, Guler R, et al. Differential effects of TNF and LTalpha in the host defense against M. bovis BCG. Eur J Immunol 2001; 31:1935.</a></li><li><a class="nounderline abstract_t">Huffnagle GB, Toews GB, Burdick MD, et al. Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. J Immunol 1996; 157:4529.</a></li><li><a class="nounderline abstract_t">Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A 1997; 94:8093.</a></li><li><a class="nounderline abstract_t">Mehrad B, Strieter RM, Standiford TJ. Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis. J Immunol 1999; 162:1633.</a></li><li><a class="nounderline abstract_t">Randhawa PS. Lymphocyte subsets in granulomas of human tuberculosis: an in situ immunofluorescence study using monoclonal antibodies. Pathology 1990; 22:153.</a></li><li><a class="nounderline abstract_t">Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3:148.</a></li><li class="breakAll">World Health Organization. Expert Committee on Biological Standardization.  Guidelines on evaluation of similar biotherapeutic products. Geneva, 2009. http://www.who.int/biologicals/areas/biological_ (Accessed on September 28, 2013).</li><li><a class="nounderline abstract_t">Kerschbaumer A, Sepriano A, Bergstra SA, et al. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2023; 82:95.</a></li><li><a class="nounderline abstract_t">Serio RN. Infliximab treatment of sarcoidosis. Ann Pharmacother 2003; 37:577.</a></li><li><a class="nounderline abstract_t">Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124:177.</a></li><li><a class="nounderline abstract_t">Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121:1088.</a></li><li><a class="nounderline abstract_t">Mocci G, Marzo M, Papa A, et al. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohns Colitis 2013; 7:769.</a></li><li><a class="nounderline abstract_t">Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 2013; 65:28.</a></li><li><a class="nounderline abstract_t">Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337:141.</a></li><li><a class="nounderline abstract_t">Emery P, Vencovský J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2017; 76:51.</a></li><li><a class="nounderline abstract_t">Smolen J, Landewé RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68:797.</a></li><li><a class="nounderline abstract_t">Weinblatt ME, Fleischmann R, Huizinga TW, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology (Oxford) 2012; 51:2204.</a></li><li><a class="nounderline abstract_t">Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009; 68:789.</a></li><li><a class="nounderline abstract_t">Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98:1315.</a></li><li><a class="nounderline abstract_t">Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005; 72:250.</a></li><li><a class="nounderline abstract_t">Vultaggio A, Matucci A, Nencini F, et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010; 65:657.</a></li><li><a class="nounderline abstract_t">Kapetanovic MC, Larsson L, Truedsson L, et al. Predictors of infusion reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther 2006; 8:R131.</a></li><li><a class="nounderline abstract_t">Yun H, Xie F, Beyl RN, et al. Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2017; 69:1526.</a></li><li><a class="nounderline abstract_t">Puig Sanz L, Sáez E, Lozano MJ, et al. [Reactions to infliximab infusions in dermatologic patients: consensus statement and treatment protocol. Working Group of the Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología ]. Actas Dermosifiliogr 2009; 100:103.</a></li><li><a class="nounderline abstract_t">Hastings R, Ding T, Butt S, et al. Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken) 2010; 62:764.</a></li><li class="breakAll">Prescribing information, Etanercept (Enbrel®) Immunex Corporation, 10/10/2000.</li><li><a class="nounderline abstract_t">van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47:1531.</a></li><li><a class="nounderline abstract_t">TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1999; 53:457.</a></li><li><a class="nounderline abstract_t">Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44:2862.</a></li><li><a class="nounderline abstract_t">Simsek I, Erdem H, Pay S, et al. Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 2007; 66:1255.</a></li><li><a class="nounderline abstract_t">Shin IS, Baer AN, Kwon HJ, et al. Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 2006; 54:1429.</a></li><li><a class="nounderline abstract_t">Eguren C, Díaz Ley B, Daudén E, et al. Peripheral neuropathy in two patients with psoriasis in treatment with infliximab. Muscle Nerve 2009; 40:488.</a></li><li><a class="nounderline abstract_t">Winthrop KL, Chen L, Fraunfelder FW, et al. Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol 2013; 155:183.</a></li><li><a class="nounderline abstract_t">Dreyer L, Magyari M, Laursen B, et al. Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry. Ann Rheum Dis 2016; 75:785.</a></li><li><a class="nounderline abstract_t">Delcoigne B, Kopp TI, Arkema EV, et al. Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers. RMD Open 2023; 9.</a></li><li><a class="nounderline abstract_t">Kwon HJ, Coté TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138:807.</a></li><li><a class="nounderline abstract_t">Gabriel SE. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis? Arthritis Rheum 2008; 58:637.</a></li><li><a class="nounderline abstract_t">Ljung L, Askling J, Rantapää-Dahlqvist S, et al. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. Arthritis Res Ther 2014; 16:R127.</a></li><li><a class="nounderline abstract_t">Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70:576.</a></li><li><a class="nounderline abstract_t">Ozen G, Pedro S, Michaud K. The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. J Rheumatol 2021; 48:648.</a></li><li><a class="nounderline abstract_t">Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109:1594.</a></li><li><a class="nounderline abstract_t">Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002; 86:123.</a></li><li><a class="nounderline abstract_t">Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107:3133.</a></li><li class="breakAll">Schiff MH, Burmester GR, Pangan AL et al. Safety of adalimumab (Humira) in global clinical trials of patients with early vs. longstanding rheumatoid arthritis (RA) (abstract SAT0044). Presented at the Annual European Congress of Rheumatology (EULAR), Vienna, Austria, 2005.</li><li class="breakAll">Kent JD, Pangan AL, Fitzpatrick SB. Analysis of the US postmarketing safety of adalimumab (HUMIRA) in patients with rheumatoid arthritis during the first 2 years after approval (abstract). Presented at American College of Rheumatology Annual Meeting, San Diego, 2005.</li><li><a class="nounderline abstract_t">Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004; 116:305.</a></li><li><a class="nounderline abstract_t">Solomon DH, Rassen JA, Kuriya B, et al. Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. Ann Rheum Dis 2013; 72:1813.</a></li><li><a class="nounderline abstract_t">Schau T, Gottwald M, Arbach O, et al. Increased Prevalence of Diastolic Heart Failure in Patients with Rheumatoid Arthritis Correlates with Active Disease, but Not with Treatment Type. J Rheumatol 2015; 42:2029.</a></li><li><a class="nounderline abstract_t">Cole J, Busti A, Kazi S. The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists. Rheumatol Int 2007; 27:369.</a></li><li><a class="nounderline abstract_t">Khasnis AA, Calabrese LH. Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk. Semin Arthritis Rheum 2010; 40:147.</a></li><li><a class="nounderline abstract_t">Dixon WG, Hyrich KL, Watson KD, et al. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010; 69:1086.</a></li><li class="breakAll">United States Food and Drug Administration. 2004 Safety alerts for drugs, biologics, medical devices, and dietary supplements. www.fda.gov/medwatch/SAFETY/2004/safety04.htm#Remicade2 (Accessed on January 04, 2004).</li><li><a class="nounderline abstract_t">Lopetuso LR, Mocci G, Marzo M, et al. Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver. Int J Mol Sci 2018; 19.</a></li><li><a class="nounderline abstract_t">Sokolove J, Strand V, Greenberg JD, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69:1612.</a></li><li><a class="nounderline abstract_t">Choi SJ, Oh JS, Hong S, et al. Liver enzyme elevation in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors: a single-center historical cohort study. Korean J Intern Med 2020; 35:723.</a></li><li><a class="nounderline abstract_t">Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009; 68:209.</a></li><li><a class="nounderline abstract_t">Joyau C, Veyrac G, Dixneuf V, Jolliet P. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol 2012; 30:700.</a></li><li><a class="nounderline abstract_t">Wollina U, Hansel G, Koch A, et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008; 9:1.</a></li><li><a class="nounderline abstract_t">Kip KE, Swoger JM, Grandinetti LM, et al. Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system. Inflamm Bowel Dis 2013; 19:1164.</a></li><li><a class="nounderline abstract_t">Hu JZ, Billings SD, Yan D, Fernandez AP. Histologic comparison of tumor necrosis factor-α inhibitor-induced psoriasis and psoriasis vulgaris. J Am Acad Dermatol 2020; 83:71.</a></li><li><a class="nounderline abstract_t">Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010; 40:233.</a></li><li><a class="nounderline abstract_t">Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007; 156:486.</a></li><li><a class="nounderline abstract_t">Asarch A, Gottlieb AB, Lee J, et al. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol 2009; 61:104.</a></li><li><a class="nounderline abstract_t">Béné J, Moulis G, Auffret M, et al. Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database. Rheumatology (Oxford) 2014; 53:1465.</a></li><li><a class="nounderline abstract_t">Hernández MV, Sanmartí R, Cañete JD, et al. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. Arthritis Care Res (Hoboken) 2013; 65:2024.</a></li><li><a class="nounderline abstract_t">Cleynen I, Van Moerkercke W, Billiet T, et al. Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study. Ann Intern Med 2016; 164:10.</a></li><li><a class="nounderline abstract_t">Fréling E, Baumann C, Cuny JF, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol 2015; 110:1186.</a></li><li><a class="nounderline abstract_t">George LA, Gadani A, Cross RK, et al. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease. Dig Dis Sci 2015; 60:3424.</a></li><li><a class="nounderline abstract_t">Soh JS, Yun WJ, Kim KJ, et al. Concomitant use of azathioprine/6-mercaptopurine decreases the risk of anti-TNF-induced skin lesions. Inflamm Bowel Dis 2015; 21:832.</a></li></ol></div><div id="topicVersionRevision">Topic 7970 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27258623" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2540776" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The biology of cachectin/TNF--a primary mediator of the host response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11244034" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15093829" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Tumor necrosis factor family ligand-receptor binding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11971010" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20466271" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Infectious complications associated with immunomodulating biologic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2647299" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9637524" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9464804" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : High sensitivity of transgenic mice expressing soluble TNFR1 fusion protein to mycobacterial infections: synergistic action of TNF and IFN-gamma in the differentiation of protective granulomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7540941" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10451499" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Different types of pulmonary granuloma necrosis in immunocompetent vs. TNFRp55-gene-deficient mice aerogenically infected with highly virulent Mycobacterium avium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11433391" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Differential effects of TNF and LTalpha in the host defense against M. bovis BCG.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8906831" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9223320" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Characterization of tumor necrosis factor-deficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9973423" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2243727" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Lymphocyte subsets in granulomas of human tuberculosis: an in situ immunofluorescence study using monoclonal antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12614731" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12614731" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36368906" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12659618" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Infliximab treatment of sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12853521" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11677200" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23453887" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23169319" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9219699" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26150601" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19015207" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22923753" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19066176" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12818276" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The incidence and management of infusion reactions to infliximab: a large center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16021319" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Monoclonal antibodies, immunogenicity, and associated infusion reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19951375" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16869978" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Predictors of infusion reactions during infliximab treatment in patients with arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27813327" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19445874" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : [Reactions to infliximab infusions in dermatologic patients: consensus statement and treatment protocol. Working Group of the Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología ].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20535786" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Neutropenia in patients receiving anti-tumor necrosis factor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20535786" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Neutropenia in patients receiving anti-tumor necrosis factor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8960740" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10449104" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11762947" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17456525" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Optic neuritis occurring with anti-tumour necrosis factor alpha therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16645971" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Guillain-Barréand Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19623630" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Peripheral neuropathy in two patients with psoriasis in treatment with infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22967869" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26698850" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36854568" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12755552" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Case reports of heart failure after therapy with a tumor necrosis factor antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18311805" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24941916" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21109516" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32801134" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15023878" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12419548" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796126" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796126" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796126" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14984815" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23155221" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26373561" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Increased Prevalence of Diastolic Heart Failure in Patients with Rheumatoid Arthritis Correlates with Active Disease, but Not with Treatment Type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17028862" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19914686" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20444754" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20444754" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30060508" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-αon the Liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20448284" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31870134" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Liver enzyme elevation in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors: a single-center historical cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18385277" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22935567" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18092839" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23518804" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Tumor necrosis factorαantagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31931086" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Histologic comparison of tumor necrosis factor-αinhibitor-induced psoriasis and psoriasis vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20580412" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17300238" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19539844" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24681837" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23926075" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26641955" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26195181" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26115749" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25789922" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Concomitant use of azathioprine/6-mercaptopurine decreases the risk of anti-TNF-induced skin lesions.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
